Introduction
============

Human Embryonic stem cells (hESCs) are the potential therapeutic targets for various chronic/terminal conditions ([@b1-ijsc-11-105]). hESC lines are excellent candidates in transplantation medicine because they have the capacity to grow indefinitely in culture without losing pluripotency ([@b2-ijsc-11-105]). The first FDA approved clinical trial of hESCs therapy was conducted in 2009; a product derived from hESCs was applied for stimulating nerve growth in patients ([@b3-ijsc-11-105]). But, the clinical transplantation of hESCs requires immunosuppressive therapy as immune rejection is the bottleneck which hinders the application of hESCs as transplantation therapy ([@b4-ijsc-11-105]).

The underline cause of immune rejection are the major histocompatibility antigens (cell surface antigens), essential for the acquired immune system which usually vary between the donor and host as they are perceived as non self by the recipient's immune system ([@b5-ijsc-11-105], [@b6-ijsc-11-105]). Swijnenburg and his co-workers proved that the embryonic stem cells (ESC) trigger an accelerated infiltration of immune cells, indicating the immune response towards developing ESCs in allotransplant (genetically non-identical) that increases over time ([@b7-ijsc-11-105]). Similarly, Fandrich and his co-workers showed that the rat ESC-like cells express very low levels of major histocompatibility complex (MHC) -I antigens and completely lack MHC-II and co stimulatory molecules. This helps to decrease the chances of immune rejection as the donor MHC is absent that could mismatch with the recipient's MHC ([@b8-ijsc-11-105]). Low levels of MHC-I result in escape of hESCs from an immune rejection ([@b9-ijsc-11-105]). But, low levels of MHC I antigen increases after differentiation both *in vitro* and *in vivo* and is sufficient for immune rejection ([@b10-ijsc-11-105], [@b11-ijsc-11-105]). The present study describes hESCs of pre-blastomeric origin derived at 2-celled stage and cultured using a patented technology that do not induce any immune rejection. The study also describes the differentially expressed genes profile and their related pathways for immune reactions.

Materials and Methods
=====================

Origin of cell line
-------------------

The study was approved by an independent ethics committee (IEC). Cell lines used in this study were cultured from a spare fertilized ovum obtained during natural *in vitro* fertilization (IVF) process with due consent from the donor. The hESCs were cultured and maintained as per our patented technology (United States Granted Patent No US 8592, 208, 52) in a good manufacturing practice (GMP), good laboratory practice (GLP) and good tissue practice (GTP) compliant laboratory. The cell lines were stable and free from any contamination. The detailed cell culture and differentiation techniques are explained in our previous paper ([@b12-ijsc-11-105]).

Cell culture and derivation
---------------------------

The fertilized ovum was suspended in Roswell Park Memorial Institute medium (RPMI) and broken by mechanical means. *β*hCG and progestin was added and the cells were incubated in a CO~2~ water jacketed incubator for 24 hrsin an aerobic condition. The cell suspension was divided into two and one of them was re-incubated in the same incubator after adding Dulbecco's Modified Eagle's Medium (DMEM, Himedia Labs, Mumbai, India) and the other in RPMI in anaerobic condition. The details of the cell culture and derivation are detailed in our previous paper ([@b12-ijsc-11-105]).

RNA extraction and RT-PCR
-------------------------

Three samples were selected for the polymerase chain reaction (PCR) analysis and RNA extraction was performed using Qiagen RNeasy micro kit. RNA concentration was estimated using Nanodrop spectrophotometer. RNA purity and integrity were checked by employing an Agilent Bioanalyzer. The cDNA synthesis and primer sequences and annealing temperatures for genes Nestin, Sox 2, HLA-G and *β*-HCG are mentioned in our previous paper ([@b12-ijsc-11-105]). *β*-actin gene was used as house keeping control gene. The amplified PCR products were analyzed by electrophoresis on 1% agarose gels.

miRNA microarray analysis
-------------------------

Samples were hybridized for microarray experiment. microRNA (miRNA) molecules in total RNA were labeled with Agilent miRNA labeling reagent and hybridization kit (Cat \# 5190-0456). Labeling method used ligation of one cyanine 3--pCp molecule to the 3'end of RNA molecule with greater than 90% efficiency that generates fluorescent miRNA. After hybridization, the samples were scanned with Agilent Scanner. Images were analyzed using Agilent's Feature extraction software. Raw data was normalized using GeneSpring GX 12.6 software. Complete miRNA in the array detected on the basis of intensities.

For filtering the high expression miRNA from complete, lobase 2 value ≥0.6 was used. The target genes for differentially regulated miRNA's for up-regulation and down-regulation were checked using GeneSpring GX 12.6 software with an integrated target scan database.

Functional annotation analysis
------------------------------

To examine the gene pool of detected miRNA, Database for Annotation, Visualization and Integrated Discovery (DAVID)was used ([@b13-ijsc-11-105]). It covers more than 40 annotation categories, including Gene Ontology (GO; [www.geneontology.org/](www.geneontology.org/)) terms, protein--protein interactions, protein functional domains, disease associations and biological pathways. GO terms organize genes into hierarchical categories consisting of three main layers and the first layer included three branches: biological process, cellular component and molecular function.

We analyzed the potential target genes associated pathways as per the Kyoto Encyclopedia of Genes and Genomes, Reactome and Panther pathway database ([@b14-ijsc-11-105]--[@b16-ijsc-11-105]). A p value of \<0.05 was used as the cut-off criterion.

Results
=======

The hESC cell line analyzed was a mixture of the two cell lines; neuronal and non-neuronal. Thus, the analysis plan is focused on both of them. Mixture batch (M-batch) which is a mixture of both the cell lines was used as a control to compare the analysis of neuronal and non-neuronal cell lines.

Cell line differentiation
-------------------------

Differentiation of the hESC line into neuronal and non-neuronal cells was observed under appropriate culture conditions on DMEM and RPMI media. The detailed protocol is explained in our previous paper. hESCs expressed high levels of nestin (neuronalprogenital cells, NPCs) and NeuN (neuronal marker undifferentiated cells) which indicates the neuronal differentiation nature of these cells ([@b12-ijsc-11-105]).

RNA Quality Control (QC) check
------------------------------

All the three samples were found to be suitable for microarray experiments as they showed high purity and concentration of RNA.

Surface markers analyzed by RT-PCR
----------------------------------

Markers expression for HLA-G, a major histocompatible factor, 5-methyl cytosine gene activation marker, telomerase maintenance of genomic integrity and pluripotency of stem cells and *β*- human chorionic gonadotropin (*β*-hCG) which is an immune modulator was found to be amplified indicating that these genes are present and expressive in hESCs at mRNA level. Expression profile of all the markers was explained in our previous paper ([@b12-ijsc-11-105]).

miRNA potential target gene analysis
------------------------------------

Hybridized samples predicted the differentially expressed miRNA in the individual test sample. Each miRNA has a unique mirbase accession number and ability to regulate the expression of several hundred target genes. GeneSpring GX provided the gene target and their location on chromosome for each miRNA as shown in [Table 1](#t1-ijsc-11-105){ref-type="table"}. Hence, GO term and their description for each miRNA target gene was determined for immune reactions.

Functional analysis
-------------------

Biological processes of the predicted miRNAs gene targets were classified by GO analysis. Genes involved in each pathway are then determined by Reactome and Panther databases. Significant p-values showed the up and downregulation of genes involved in various pathways of immune rejection ([Table 2](#t2-ijsc-11-105){ref-type="table"}). After differentiation of the cell lines, MHC-I receptor activity (p=0.0059), MHC-I protein complex (p=0.0057) and total MHC protein complex (p=0.0284) had statistically significant values, implying that their function and pathways are down-regulated and hence the expression of MHC-I on hESCs is low. Antigen processing and presentation of peptide antigen via MHC-I was significant (p=0.0269) indicating a higher potential of MHC-I to process the antigen only if they are present on hESCs. MHC -II receptor activity, and for protein binding in MHC-II class protein showed down-regulation (p=1.000) which states that the hESCs did not express MHC-II. Our results clearly prove that B-cell lymphoma-2 (BCL 2) is involved in B cell lineage commitment (p=1.00), B cell differentiation (p=0.0678), B cell activation (p=0.1873), B cell homeostasis (p=0.1959), T cell selection, differentiation and activation (p=0.4509), humoral immune response (p=0.4611) and all these processes are down-regulated indicating that these functional processes are absent in hESCs. Thymocyte differentiation antigen 1 (THY1) is involved in immune system development (p=0.1764), immune surface receptor signaling pathway (p=0.5388), activation of immune response (p=0.5535), positive regulation of immune system process (p=0.6905), regulation of immune response (p=0.8240) and for all these processes GO analysis showed the down-regulation suggesting that the immune response to hESCs is down-regulated by THY1.

Discussion
==========

Since hESCs were first isolated, it has been widely accepted that these cells hold the potential to change the face of medicine as they have the capacity to differentiate in every cell type of the human body ([@b17-ijsc-11-105]). But, the immune rejection by the patients' immune system acts as a barrier to the hESC therapy ([@b18-ijsc-11-105]).

Previous experiments conducted by Drukker and his co-workers observed that in the mouse strains with different types of immune deficiency, T cell-deficient animals failed to reject hESC-derived graft, whereas the lack of NK cells or B-cells did not interfere with hESC rejection; thus suggesting that T cells play a pivotal role in the rejection of hESCs and their differentiated derivatives ([@b19-ijsc-11-105]). Our results showed a down regulation for T cell activation indicating that the hESCs are unable to induce proliferation of T cell population in the host, thus, these hESCs can easily escape immune rejection pathway. It has also been proven that hESCs are able to inhibit T cell proliferation in response to allogeneic antigen presenting dendritic cell ([@b20-ijsc-11-105]). Immune system is regulated by several genes but BCL 2 plays a major role. BCL 2 is an anti-apoptotic gene and it regulates cell differentiation processes. Our results showed that BCL 2 down regulates the B-cell and T-cell activation; thus, the functional processes of B-cell and T-cell activation are absent in hESCs.

It was recently suggested that immunological maturity or expression of antigens on the surface of hESCs is a late event during the gestational period of human embryos ([@b21-ijsc-11-105]). Our microarray data support this notion. The expression of immune related genes, MHC-I and MHC-II was not up-regulated during *in vitro* differentiation of hESCs. These hESCs were of pre-blastomeric origin and at 2-celled stage; wherein the levels of expression of MHC-I and MHC-II are almost negligible ([@b12-ijsc-11-105]). Besides, hESCs might provoke less of an immune response because expression of MHC-I and MHC-II protein was not detected on the surface of either undifferentiated or their differentiated progeny ([@b20-ijsc-11-105]) But, hESCs express high levels of MHC-I after differentiation both *in vitro* and *in vivo* hence hESCs can be rejected on transplantation ([@b9-ijsc-11-105]). However, our results proved that after pre differentiation, the expression of MHC class I protein complex (p=0.0057), and MHC class I receptor activity (p=0.0059) showed a down-regulation which means that hESCs grown at our facility showed low levels of MHC-I and MHC-II even after differentiation and hence are capable to escape an immune rejection. We have transplanted these cell lines in over 1,400 patients with terminal conditions where the traditional therapies had not worked and found them to be safe and effective. For all these patients, we did not observe an immune reaction. We have never administered any immunosuppressant to these patients ([@b22-ijsc-11-105]--[@b26-ijsc-11-105]).

Another key player of immune system activation is THY1 also known as CD90. It is a cell surface antigen which has neuronal expression in nervous system and is found to activate the immune system processes. Since, hESCs have no antigens expressed on their surface and are not involved in any immune reaction; thus, the host cells are not able to identify the injected hESC as foreign and the pathway for immune rejection is down-regulated.

Conclusion
==========

The present study revealed that the hESCs cultured at our facility are non-immunogenic as they express very low levels of MHC-I and MHC-II. These hESCs found to be suitable for transplantation without the use of immunosuppressant and are universal in their applicability.
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###### 

Protein coding gene targets for miRNA's analyzed by GeneSpring GX

  Sr. No   Mirbase accession number     GO term      GO_Process                                       Full name                                                                                      Chromosome location   p-value
  -------- ---------------------------- ------------ ------------------------------------------------ ---------------------------------------------------------------------------------------------- --------------------- ---------
  1        MIMAT0005828                 GO:0030183   B-cell Differentiation                           ADP-ribosylation factor-like 1                                                                 2                     0.0582
  2        MIMAT0005828                 GO:0030183   B-cell Differentiation                           B-cell CLL/lymphoma 11A (zinc finger protein)                                                  2                     0.0683
  3        MIMAT0005828                 GO:0030183   B-cell Differentiation                           Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)   10                    0.0808
  4        MIMAT0005828                 GO:0030183   B-cell Differentiation                           Histone deacetylase 4                                                                          2                     0.1070
  5        MIMAT0005828                 GO:0030183   B-cell Differentiation                           Enhancer binding protein (C/EBP), gamma                                                        19                    0.1683
  6        MIMAT0005828                 GO:0030183   T cell receptor signaling pathway                Phosphoinositide-3-kinase, regulatory subunit 1 (alpha)                                        5                     0.1795
  7        MIMAT0005828                 GO:0030183   B-cell Differentiation                           One cut homeobox 1                                                                                                   0.2662
  8        MIMAT0005865                 GO:0002520   Immune system development                        SMAD family member 3                                                                           15                    0.6051
  9        MIMAT0005865                 GO:0042113   B cell activation                                Taxilin alpha                                                                                  1                     0.6462
  10       MIMAT0005828                 GO:0042113   Immune response-activating signal transduction   src kinase associated phosphoprotein 2                                                                               0.4767
  11       MIMAT0005828, MIMAT0005878   GO:0042113   B cell activation                                                                                                                               7                     0.3143

###### 

Transcriptomic Profile of Genes

  Sr No   GO term      Description                                                              Count   \%         p-value   Genes
  ------- ------------ ------------------------------------------------------------------------ ------- ---------- --------- ------------------------------------------------------------
  1       GO:0030183   B cell differentiation                                                   4       1.005025   0.0678    BCL2, SP3, BAX, CD79A
  2       GO:0002520   Immune system development                                                9       2.261307   0.1764    HOXA3, BCL2, BAX, CD4, CD79A, FGF3, ERCC2
  3       GO:0042113   B cell activation                                                        4       1.005025   0.1873    BCL2, SP3, BAX, CD79A
  4       GO:0001782   B cell homeostasis                                                       2       0.502513   0.1959    BCL2, BAX
  5       GO:0032943   Mononuclear cell proliferation                                           3       0.753769   0.2136    BCL2, BAX, CD79A
  6       GO:0045058   T cell selection                                                         2       0.502513   0.3139    BCL2, CD4
  7       GO:0030217   T cell differentiation                                                   3       0.753769   0.3657    BCL2, SP3, CD4
  8       GO:0050870   Positive regulation of T cell activation                                 3       0.753769   0.4413    RARA, CD4, THY1
  9       GO:0042110   T cell activation                                                        4       1.005025   0.4509    BCL2, SP3, BAX, CD4
  10      GO:0006959   Humoral immune response                                                  3       0.753769   0.4611    CR2, LY86, BCL2
  11      GO:0045087   Innate immune response                                                   4       1.005025   0.5109    CYBA, CR2, IRGM, TBKBP1
  12      GO:0002429   Immune response-activating cell surface receptor signaling pathway       2       0.502513   0.5388    CD79A, THY1
  13      GO:0002253   Activation of immune response                                            3       0.753769   0.5535    CR2, CD79A, THY1
  14      GO:0045580   Regulation of T cell differentiation                                     2       0.502513   0.6367    CLPTM1, RARA
  15      GO:0002757   Immune response-activating signal transduction                           2       0.502513   0.6439    CD79A, THY1
  16      GO:0002764   Immune response-regulating signal transduction                           2       0.502513   0.6711    CD79A, THY1
  17      GO:0002684   Positive regulation of immune system process                             5       1.256281   0.6905    CR2, RARA, CD4, CD79A, THY1
  18      GO:0002252   Immune effector process                                                  3       0.753769   0.7428    CPLX2, CR2, BCL2
  19      GO:0050778   Positive regulation of immune response                                   3       0.753769   0.7811    CR2, CD79A, THY1
  20      GO:0002443   Leukocyte mediated immunity                                              2       0.502513   0.8191    CPLX2, CR2
  21      GO:0050776   Regulation of immune response                                            4       1.005025   0.8240    CR2, RARA, CD79A, THY1
  22      GO:0042287   MHC protein binding                                                      1       0.251256   1.0000    CD4
  23      GO:0042289   MHC class II protein binding                                             1       0.251256   1.0000    CD4
  24      GO:0032395   MHC class II receptor activity                                           1       0.251256   1.0000    HLA-DRB1
  25      GO:0019815   B cell receptor complex                                                  1       0.251256   1.0000    CD79A
  26      GO:0019814   Immunoglobulin complex                                                   1       0.251256   1.0000    CD79A
  27      GO:0042613   MHC class II protein complex                                             1       0.251256   1.0000    HLA-DRB1
  28      GO:0042612   MHC class I protein complex                                              9       0.418994   0.0057    AZGP1, MICA, ULBP1, ULBP2, HLA-A, HFE, HLA-C, HLA-G, HLA-F
  29      GO:0032393   MHC class I receptor activity                                            7       0.325885   0.0059    MICA, ULBP1, ULBP2, HLA-A, HLA-C, HLA-G, HLA-F
  30      GO:0002474   Antigen processing and presentation of peptide antigen via MHC class I   1       0.263158   1.0000    HLA-E

Count- Number of genes in the respective term. %- Percentage of involved genes/total genes.
